Cipla to announce Q2 results: Revenue likely to grow around 8.4%; profit expected at Rs 468 crore

Pharma company Cipla will be announcing its quarterly results on Monday.

The key thing to watch out for will be margins. Last quarter the margins had improved to around 18.5 percent odd.

This quarter the street is expecting the margins to come around 19 percent odd which would be flat year-on-year and a bit of an improvement on quarter-on-quarter basis.

Revenue is expected to grow around 8.4 percent with profit coming at Rs 468 crore.

US business is expected to be aided by limited competition drugs like Reyataz, Voltaren generic.

30 percent of the US revenue will be derived from the products launched over the last 12 months.

Domestic business growth may be impacted by poor anti-infective season and GST restocking.